BIOCON LIMITED. Valuation

BIOCON · Healthcare · Current price ₹399.95

Full stock page
DocStoX fair value
₹196
low confidence
Current price
₹400
Upside
-50.9%
P/E ratio
168.1x
P/B ratio
2.0x
Verdict
Avoid
Model it yourself — Earnings Yield Calculator
Opens pre-filled with BIOCON LIMITED.'s latest numbers.

Is BIOCON LIMITED. undervalued?

DocStoX estimates the fair value of BIOCON LIMITED. at ₹196 per share, versus the current market price of ₹400. That puts the stock about -50.9% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 4 independent methods: Residual income (₹183), Relative P/E (₹83), Graham floor (₹106), Analyst target (₹441). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹83 (bear) to ₹196 (base) to ₹441 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Valuation multiples

BIOCON LIMITED. trades at a P/E of 168.1x and a P/B of 2.0x, with a dividend yield of 0.1%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.

Understand the ratios

P/E RatioP/B RatioPEG RatioEarnings Yield

More on BIOCON LIMITED.

Fair ValueIntrinsic ValueDCFFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.